Literature DB >> 20843201

Nanobodies®: proficient tools in diagnostics.

Lieven Huang1, Serge Muyldermans, Dirk Saerens.   

Abstract

With the advent of new antibody engineering technologies, conventional antibodies have been minimized into smaller antibody formats. Small size is an important advantage for current and future diagnostic development. Nanobodies® (Ablynx) are among the smallest known antigen-binding antibody fragments, and are derived from the heavy-chain only antibodies that occur naturally in the serum of Camelidae. Endowed by natural evolution, these Nanobodies inherently exhibit unique biophysical, biochemical and pharmacological characteristics. In addition to their excellent potential as molecules in drug development, Nanobodies possess very attractive functional properties that aid in their development for diagnostic tools. Here we present several examples of currently available applications of Nanobodies to the field of immunosensor for cancer, immunoaffinity chromatography, in vivo and intracellular imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843201     DOI: 10.1586/erm.10.62

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  21 in total

Review 1.  Guide to Selecting a Biorecognition Element for Biosensors.

Authors:  Marissa A Morales; Jeffrey Mark Halpern
Journal:  Bioconjug Chem       Date:  2018-09-28       Impact factor: 4.774

2.  Engineered high-affinity nanobodies recognizing staphylococcal Protein A and suitable for native isolation of protein complexes.

Authors:  Peter C Fridy; Mary K Thompson; Natalia E Ketaren; Michael P Rout
Journal:  Anal Biochem       Date:  2015-02-21       Impact factor: 3.365

3.  Characterization of rabbit polyclonal antibody against camel recombinant nanobodies.

Authors:  Houssam-Eddin Khalaf; Hassan Al-Bouqaee; Manal Hwijeh; Abdul Qader Abbady
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

4.  Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-11-15       Impact factor: 2.408

Review 5.  Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Authors:  Nairo Brilhante-da-Silva; Rosa Maria de Oliveira Sousa; Andrelisse Arruda; Eliza Lima Dos Santos; Anna Carolina Machado Marinho; Rodrigo Guerino Stabeli; Carla Freire Celedonio Fernandes; Soraya Dos Santos Pereira
Journal:  Mol Diagn Ther       Date:  2021-06-19       Impact factor: 4.074

Review 6.  Immunochemical methods for ochratoxin A detection: a review.

Authors:  Eline P Meulenberg
Journal:  Toxins (Basel)       Date:  2012-04-13       Impact factor: 4.546

Review 7.  Biotechnological applications of recombinant single-domain antibody fragments.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2011-06-09       Impact factor: 5.328

8.  In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease.

Authors:  Rob J A Nabuurs; Kim S Rutgers; Mick M Welling; Athanasios Metaxas; Maaike E de Backer; Maarten Rotman; Brian J Bacskai; Mark A van Buchem; Silvère M van der Maarel; Louise van der Weerd
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

9.  A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting.

Authors:  Shan-Mei Wang; Xian He; Nan Li; Feng Yu; Yang Hu; Liu-Sheng Wang; Peng Zhang; Yu-Kui Du; Shan-Shan Du; Zhao-Fang Yin; Ya-Ru Wei; Xavier Mulet; Greg Coia; Dong Weng; Jian-Hua He; Min Wu; Hui-Ping Li
Journal:  Int J Nanomedicine       Date:  2015-04-13

10.  High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain.

Authors:  Annika Järviluoma; Tomas Strandin; Sebastian Lülf; Jérôme Bouchet; Anna R Mäkelä; Matthias Geyer; Serge Benichou; Kalle Saksela
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.